Religare Enterprises Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated income of ₹4,717 crore for H1 FY27, a 19% YoY growth. Key subsidiaries also showed positive performance, with Care Health Insurance GWP growing 35% and Religare Finvest PAT up 33%. The board was also strengthened with the approval of new directors by the RBI.
Religare Enterprises H1 FY27 Financial Highlights
Religare Enterprises Limited (REL) has announced its financial results for the second quarter and the first half of the financial year 2026-27, ending September 30, 2026. The company reported a consolidated income of ₹4,717 crore for the half-year ended September 30, 2026, marking a significant 19% year-over-year growth compared to ₹3,965 crore in the corresponding period of the previous year.
Subsidiary Performance Updates
Care Health Insurance Limited (CHIL) demonstrated robust growth, with its Gross Written Premium (GWP) increasing by 35% YoY to ₹6,897 crore in H1 FY27. Profit Before Tax (PBT) for CHIL saw a 42% YoY increase, reaching ₹392 crore.
Religare Finvest Limited (RFL), a wholly-owned subsidiary, reported a 33% YoY growth in its Profit After Tax (PAT) for H1 FY27, amounting to ₹64.5 crore. RFL has a Net Worth of approximately ₹963 crore and a debt-free balance sheet. Notably, RFL resumed lending activities in November 2026, opening new branches and disbursing its first loan.
Religare Broking Limited (RBL) also showed improved performance, with its H1 FY27 Profit Before Tax (PBT) growing by 29% YoY to ₹13.0 crore. The company’s Assets Under Custody stood at ₹56,576 crore as of September 30, 2026.
Governance and Other Developments
The company also provided an update on its governance review, concluding that there were no financial implications or material adverse impacts identified from the review conducted by M/s Trilegal. The Board of Directors was further strengthened with the Reserve Bank of India (RBI) approving the appointment of four new Directors: Dr. Anand Burman, Mr. Mohit Burman, Mr. Aditya Burman, and Mr. Jimeet Modi.
Source: BSE
